These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38958425)
41. Relay: A Peer-Delivered Emergency Department-Based Response to Nonfatal Opioid Overdose. Welch AE; Jeffers A; Allen B; Paone D; Kunins HV Am J Public Health; 2019 Oct; 109(10):1392-1395. PubMed ID: 31415200 [TBL] [Abstract][Full Text] [Related]
42. Perception of Resource Allocations to Address the Opioid Epidemic. Strickland JC; Victor G; Ray B J Addict Med; 2022 Sep-Oct 01; 16(5):563-569. PubMed ID: 36201678 [TBL] [Abstract][Full Text] [Related]
43. Legacies of the war on drugs: Next of kin of persons who died of opioid overdose and harm reduction interventions in Philadelphia. Uzwiak BA; Hudgins A; Pizzicato LN Int J Drug Policy; 2021 Nov; 97():103351. PubMed ID: 34252788 [TBL] [Abstract][Full Text] [Related]
44. Opioid Use Disorder Stigma and Support for Harm Reduction in Rural Counties. Whipple CR; Kaynak Ö; Kruis NE; Saylor E; Bonnevie E; Kensinger WS Subst Use Misuse; 2023; 58(14):1818-1828. PubMed ID: 37622487 [No Abstract] [Full Text] [Related]
45. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone. Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501 [TBL] [Abstract][Full Text] [Related]
47. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. Hill LG; Evoy KE; Reveles KR J Am Pharm Assoc (2003); 2019; 59(6):779-782. PubMed ID: 31402146 [TBL] [Abstract][Full Text] [Related]
48. Prevalence and correlates of carrying naloxone among a community-based sample of opioid-using people who inject drugs. Reed M; Wagner KD; Tran NK; Brady KA; Shinefeld J; Roth A Int J Drug Policy; 2019 Nov; 73():32-35. PubMed ID: 31336291 [TBL] [Abstract][Full Text] [Related]
49. Overdose prevention: naloxone with long acting opioids. Bowman S; McKenzie M; Rich J Med Health R I; 2008 Sep; 91(9):271-2. PubMed ID: 18834043 [No Abstract] [Full Text] [Related]
50. Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process. Smart R; Grant S Int J Drug Policy; 2021 Dec; 98():103383. PubMed ID: 34340167 [TBL] [Abstract][Full Text] [Related]
51. Feasibility of paying people who use drugs cash to distribute naloxone within their networks. Lewis NM; Smeltzer RP; Baker TJ; Sahovey AC; Baez J; Hensel E; Poole B; Stewart C; Cogan AG; Bullard M; Taylor JL Harm Reduct J; 2024 Feb; 21(1):42. PubMed ID: 38365734 [TBL] [Abstract][Full Text] [Related]
52. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Irvine MA; Kuo M; Buxton JA; Balshaw R; Otterstatter M; Macdougall L; Milloy MJ; Bharmal A; Henry B; Tyndall M; Coombs D; Gilbert M Addiction; 2019 Sep; 114(9):1602-1613. PubMed ID: 31166621 [TBL] [Abstract][Full Text] [Related]
53. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin. Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278 [TBL] [Abstract][Full Text] [Related]
55. Addressing Fear of Negative Consequences of Overdose Response: A Qualitative Study of the Perceptions of Service Industry Workers Who Encounter an Opioid Overdose in an Urban Commercial District in Atlanta, Georgia. Febres-Cordero S; Thompson LM; Chalfant OS; Sherman ADF; Winiker AK; Kelly UA; Smith KM Workplace Health Saf; 2024 Jun; 72(6):244-252. PubMed ID: 38243156 [TBL] [Abstract][Full Text] [Related]
56. Twenty years of the methadone treatment protocol in Ireland: reflections on the role of general practice. Delargy I; Crowley D; Van Hout MC Harm Reduct J; 2019 Jan; 16(1):5. PubMed ID: 30654803 [TBL] [Abstract][Full Text] [Related]
57. Dispensing a Naloxone Kit at Hospital Discharge: A Retrospective QI Project. Train MK; Patel N; Thapa K; Pasho M; Acquisto NM Am J Nurs; 2020 Dec; 120(12):48-52. PubMed ID: 33214374 [TBL] [Abstract][Full Text] [Related]
58. Management of dependent use of illicit opioids. Mitchell C; Dolan N; Dürsteler KM BMJ; 2020 Mar; 368():m710. PubMed ID: 32152035 [No Abstract] [Full Text] [Related]
59. Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment. Taylor JL; Johnson S; Cruz R; Gray JR; Schiff D; Bagley SM J Gen Intern Med; 2021 Dec; 36(12):3810-3819. PubMed ID: 34159545 [TBL] [Abstract][Full Text] [Related]
60. At-a-glance - Supervised Injection Services: a community-based response to the opioid crisis in the City of Ottawa, Canada. DelVillano S; de Groh M; Morrison H; Do MT Health Promot Chronic Dis Prev Can; 2019 Mar; 39(3):112-115. PubMed ID: 30869474 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]